4th Apr 2016 07:00
4 April 2016
AIM: REDX
REDX PHARMA PLC
("Redx" or "the Company")
Issue of Equity
The Board of Redx Pharma Plc announces the issue of 6,180,197 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") in connection with the placing announced by the Company on 24 March 2016.
The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue. Following Admission, the Company's total issued share capital will comprise 71,161,406 Ordinary Shares. This number may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For more information please contact:
Redx Pharma Plc | T: 0151 706 4747 |
Neil Murray, Chief Executive Company website: redxpharma.com
| |
Cantor Fitzgerald Europe (Nomad & Broker) | T: 020 7894 7000 |
Phil Davies / Michael Reynolds
| |
KTZ Communications | T: 020 3178 6378 |
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson | |
|
About Redx Pharma Plc
www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.
Related Shares:
REDX.L